First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes

Clicks: 15
ID: 329038
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #247 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives To evaluate initial therapy with biologic and targeted synthetic DMARDs (b/tsDMARDs), compared with methotrexate, in patients with early RA. Methods We systematically reviewed and meta-analysed randomised-controlled trials comparing initial b/tsDMARDs, combined with methotrexate or as monotherapy, against methotrexate in methotrexate-naïve adults with early RA. Pairwise and network meta-analysis were performed to compare DAS28 remission attainment, with the primary analysis at 6 months and secondary analyses at 3 and 12 months. Secondary outcomes included ACR50 response and CDAI remission. Results Twenty-nine trials (13,387 participants) were included. Compared with methotrexate alone, initial b/tsDMARDs plus methotrexate significantly increased DAS28 remission at 6 months (risk ratio [RR] 1.62; 95% confidence interval [CI] 1.39-1.89), 3 months (RR 1.95; 1.47-2.57) and 12 months (RR 1.54; 1.39-1.71), with benefits also observed for CDAI remission and ACR50 response. In network meta-analysis, all b/tsDMARD classes combined with methotrexate had higher remission rates than methotrexate alone. The benefits of b/tsDMARDs plus methotrexate were greater in studies with higher baseline disease activity and a greater proportion of rheumatoid factor-positive participants. As monotherapy, b/tsDMARDs increased DAS28 remission attainment compared with methotrexate at 6 months (RR 1.81; 1.42-2.31), 3 months (RR 1.92; 1.31-2.83) and 12 months (RR 1.46; 1.25-1.71); however, at individual class level, significantly higher remission rates were observed only with tocilizumab and JAK inhibitor monotherapy. Conclusion Initial therapy with b/tsDMARDs in combination with methotrexate is associated with higher remission rates than methotrexate alone in patients with early RA. As monotherapy, higher remission rates were observed for JAK inhibitors and tocilizumab.
Reference Key
openalex_W7213532005 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mark Russell, Chun Jackie Chan, Aran Sasitharan, Victoria Allen, Mark Gibson, Maryam Adas, Samantha Goodliffe, Katie Bechman, Andrew P. Cope, Sam Norton, Ailsa Bosworth, P. Foxton, Elizabeth Price, Sana Sharrack, Shouvik Dass, Paul Emery, Lesley Kay, Peter Lanyon, James Galloway
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag515
URL
https://doi.org/10.1093/rheumatology/keag515
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.